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1. Introduction 
"Lupus", from the Latin in the 19th century, had appeared in the West before and after the 
medical literature. In 1828, the French dermatologist Bette (Biett) firstly reported such a 
patient: facial skin has erythema the same as the the wolf bites. To the mid-19th century, 
there was a doctor named Carson Musharraf formally using the "lupus" (lupus 
erythematosus, LE) as the medical terminology, which only refered to skin lesions of discoid 
lupus erythematosus then. With the development of medical science and clinical practice, 
more and more doctors found that lupus is not only skin damage, but also associated with 
kidney, brain, heart, lungs, nerves, muscles and joints, blood and other systemic diseases. To 
the 1890s, American doctor Osler (Osler) proposed the disease as "systemic lupus 
erythematosus" (systemic lupus erythematosus, SLE) [1].  Systemic lupus erythematosus 
(SLE), a common autoimmune disease without explicit etiology, has a high incidence of 
secondary infection, treatment difficulties and high mortality, arousing the focus of 
domestic and foreign scholars. According to the prevalence rate from 70 to 100/10 million 
people [2], China has reached to 1.12 million patients which is constituted mainly by young 
women. In addition to involving the outer skin, the disease violates various body organs, 
including vital organs such as the nervous system, heart, kidney and so on, the central 
nervous system such as meningitis, encephalitis, acute cerebrovascular disease, spinal cord 
inflammation and subarachnoid hemorrhage, even to death. It is the most common when 
occurring cardiac involvement, such as pericarditis, pericardial effusion heart attack, and 
life-threatening acute cardiac tamponade, which affect the quality of life. Involving the 
kidneys, it may be kidney failure. Respiratory system involvement includes bronchial 
pneumonia, pleurisy, atelectasis and respiratory failure. Secondary infection is a common 
complication of SLE, causing death at worst.  
 SLE is considered a typical multi-organ involvement autoimmune disease, as a result of the 
disorder of immune system[3,4]. Before the 1960s, the 5-year survival rate was below 50%. 
With the progress of the treatment and the development of therapeutic drugs, especially 
corticosteroids and cytotoxic drugs for SLE, the survival rate has improved significantly, has 
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reached 93% to the 1990s, while 10 and 20 year survival rate has reached 92%, 68%, 
respectively[5,6].  
In treatment, we begin with corticosteroid and cytotoxic at large doses the most, in order to 
suppress the disease, in 1-2 weeks, if necessary, plus corticosteroid pulse therapy or 
immunosuppressive therapy. Glucocorticoid inhibits T lymphocytes mainly through the 
production of growth factors and Fc receptor expression [7,8]. However, the dosage of 
corticosteroids varies with the insensitivity of the patients. In addition, due to large amount 
of medication for a long time, it prones to side effects and complications, such as: infection 
(viruses, bacteria, fungi, etc.), induced diabetes, peptic ulcer, perforation or gastrointestinal 
bleeding, fractures and avascular necrosis, mental disorders, Cushing's syndrome, acne, 
hirsutism, etc. More than 60% of patients died of hormonal side effects, which has bad 
impact on life quality [7]. Therefore, it is still a medical problem without effective cure. The 
latest research reports, it is an effective and new treatment for SLE by hematopoietic stem 
cell transplantation [4], the evaluation of long-term efficacy of which remains to be seen.  
Since the pathological immune T, B lymphocytes from the common lymphoid stem / 
progenitor cells, it may be an effective way to cure the disease by the application of certain 
tools (such as chemotherapy or radiotherapy) to destroy pathological immune and re-
establish normal immune system by hematopoietic stem cell transplant[3,7]. In recent years, 
it gradually become a hot topic in international research for autologous peripheral blood 
stem cell transplantation for treatment of SLE and other autoimmune diseases,whose exact 
mechanism is not fully clear, only defined to the level of the original autoimmune cell clones 
completely destroyed, while normal one re-established [7 10]. Autoimmunity and self-
tolerance is a dynamic equilibrium between the process, in which, we use 
immunosuppressive agents to weaken the strength of their immune, while hematopoietic 
stem cell transplantation to support the power of self-tolerance and eventually make the 
body's immune system normal [11]. Theoretically, it is possible to cure SLE and other 
autoimmune disease, and may achieve the purpose of healing.  
2. Materials and methods 
2.1 Clinical data 
A total of 16 patients consistent with the diagnostic criteria for SLE by American College of 
Rheumatology in 1982 were recruited, for whom corticosteroids and immunosuppressive 
therapy ineffective. There are 4 males and 12 females, aging from 11-37 years old, and the 
type of renal pathology, II, III, IV, V were3, 3, 6, 4 cases, respectively. SLEDAI scores are 14-
35 points. 
2.2 Reagents 
CD34 + cell isolation kit, Germany Miltenyi Biotec Company; Lymphocyte separation 
medium, Beijing Ding Guo; Antibody (mouse IgG1-PE, mouse anti-human CD34-PE), 
American Gene Company; 3 - aminopropyl triethoxy silane solution, a company in Kyoto, 
Japan 
2.3 Main instruments 
Immunomagnetic separation system, company Miltenyi Biotec, Germany; Blood cell 
separator,U.S. BAXTER Company; BD's flow cytometry, U.S.; Low-speed desktop 
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centrifuge,Beijing Medical Centrifuge FactoryHettich, Germany's low-temperature high-
speed centrifuge 
2.4 Hematopoietic stem cell mobilization, collection, purification and cryopreservation   
Mobilization plan: cyclophosphamide + granulocyte colony stimulating factor. We use 
cyclophosphamide intravenous 4g/m2, divided into 2 to 3 days, and urine alkalization and 
hydration to protect the heart, liver and kidney. When WBC <1.0 × 109 / L, give 
Recombinant Human Granulocyte Colony-stimulating Factor Injection 5ug/kg, until WBC> 
5.58 × 109 / L and CD34 +> 2% we start collecting with CS3000Plus blood cell separator 
(BAXTER products). After dilution and volume adjustment, plus CD34 monoclonal 
antibody in cells in 19 ~ 25 ℃ for 30 minutes, then wash 2 times by PBS buffer to pre-sort on 
MiniMACS separator, at last cool and liquid nitrogen froze immediately. 
2.5 Pre-treatment    
Cyclophosphamide 50mg/kg daily, intravenous infusion, once every 4 days (-5 to -2 days); 
ATG 2.5mg/kg.d, intravenous infusion, once every 3 days, while urine alkalization and 
hydration to protect the heart, liver and kidney. 
2.6 Hematopoietic stem cell reinfusion    
Transplant day 0, recover the frozen stem cells in 37 ℃ ~ 40 ℃water bath, then rapid 
transfusion through subclavian vein cannulation. 
2.7 Follow-up indicators  
Dynamic monitoring hematopoietic and immune indicators of clinical manifestations of SLE 
patients after transplantation. 
2.8 Statistical analysis    
We use software package SPSS10.0 processing repeated measurements analysis of variance 
of autoantibodies, immune function monitoring indicators in patients with SLE who 
underwent autologous peripheral blood stem cell transplantation. 
3. Results 
3.1 Autologous peripheral blood stem cell mobilization 
The total number of collected CD34 + cells ranged from (2.06-9.9)  108, higher than  
the required 2  106/kg, is the success of hematopoietic stem cell collection for the 16 
patients. 
3.2 Mobilization-related complications 
The total of 16 patients have leukopenia and gastrointestinal adverse reactions, and all 
with varying degrees of fever, but blood cultures were negative. 1 case has severe edema, 
but alleviate after the supplement of albumin and furosemide. 1 case has atopic dermatitis 
(specific reasons unknown), the anti-histamine treatment effective. All the patients were 
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3.3 Changes in clinical transplantation 
Within 1 month after transplantation, the facial rash, joint pain and other symptoms 
disappeared completely in all patients. 13 patients with proteinuria disappeared completely 
in three months, 3 cases of the four V-type, still urinary protein in a year, but the 24-hour 
urine protein continued to decline. One patient, 1 year after transplantation, had the 
recurrence of oral ulcers, arthralgia, leukopenia and elevated titers of autoantibodies. The 
other patient, 2 and a half years after transplantation, had facial erythema, leukopenia and 
elevated titers of autoantibodies. 
3.4 Hematopoietic reconstitution after transplantation 
The number of peripheral blood leukocytes is > 1.0×109 / L  after 7 to 15 days, platelets is > 
20×109 / L 0 to 21 days. 
3.5 Transplant-related complications 
All patients suffered from uneven serum sickness-like reactions, 1 case severe renal failure 
and heart failure, 3 cases hemorrhagic cystitis, 1 case psychogenic mental disorders, 1 case 
perineal candidiasis, 1 case acute pulmonary edema, 1 case septic shock, but all recovered 
after active treatment. 2 patients had fever after transplantation because of tuberculosis 
infection (see Chapter VII). One case with fever in October after transplantation, had chest 
CT showing: 1, multiple new lung nodules; 2, left lung consolidation; 3, pericardial 
thickening, small left pleural effusion. According to CT, it was much as the invasive nature 
of purulent bacterial or fungal infection, in combination with other manifestations, at last 
diagnosed as fungal infections, alleviated after itraconazole injection . 12 cases of 
cytomegalovirus infection became negative after ganciclovir treatment (see Chapter VI). 3 
cases of herpes zoster, 1 case of generalized herpes zoster, were recovered after treatment by 
ganciclovir. 1 case in the purification of autologous peripheral blood stem cell 
transplantation in August, appeared Evans syndrome (also known as idiopathic 
thrombocytopenic purpura with autoimmune hemolytic anemia). Check ENA polypeptide: 
ANA 70.50u/ml, ds-DNA 18.65u/ml, RNP 49.90u/ml, Sm 15.44u/ml, Coomb’s test showed: 
more than a single specific anti-human globulin (++), specific anti-C3 (+), monospecific anti-
IgG (+). Bone marrow pathology: bone marrow dysfunction, three lines of hematopoietic 
cells can be seen, the proportion of red tablets was normal, megakaryocyte number and 
morphology were without exception. Be double filtration plasmapheresis and 
methylprednisolone injection pulse therapy, Coomb’s test showed: more specific anti-
human globulin (+), single-specific anti-C3 (+), I (-). Plus immunosuppressive agents 
cyclosporine and vincristine, while reducing the hormone dosage, it is stable in clinical and 
laboratory condition. 
3.6 Post-transplant changes in autoantibody 
After transplantation ANA, anti Ds-DNA antibodies, anti-Sm antibodies, anti-RNP antibody 
titers decreased than those before transplantation, but among the different phases  they 
showed no significant ( P> 0.05), while ANA, anti-RNP antibody titers were significantly 
lower than before transplantation (P <0.05), specifically in chapter IV. 
3.7 Post-transplant immune reconstitution 
It is different for CD3 +, CD45RA + CD4 +, CD45RA + CD8 +, CD45RO + CD4 + expression 
when 3 months,6 months and 1 year after transplantation (P <0.05). (1) 3,6 month after 
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treatment, CD3 + expression levels were significantly lower than that before transplantation 
(P <0.05); (2) 6,12months after transplantation, CD45RA + CD4 + expression levels were 
significantly higher than that 3 months after transplantation (P <0.05), but no significant 
difference than before treatment (P> 0.05); (3) 3,6 months after transplantation when 
CD45RA + CD8 + expression levels were significantly lower than before transplantation ( P 
<0.05). (4) 3,6, 12 months after transplantation,  the CD45RO + CD4 + expression levels were 
significantly lower than that before transplantation (P <0.05). Detailed in Table 1. and 
Chapter. 
 
time CD3+ CD45RA+CD4+ CD45RA+CD8+ CD45RO+CD4+ 
Before 
transplantion 
74.49±9.79 5.80±3.96 28.95±11.28 16.66±5.60 
3 months later 58.04±20.61* 3.41±4.46 20.29±11.11* 8.43±3.32* 
6 months later 62.75±17.09* 6.33±4.87∆ 18.89±8.18* 10.26±4.84* 
12 months 
later 
67.28±14.16 7.84±3.63∆ 23.14±10.15 11.55±5.25* 
F  3.727 4.457 4.539 8.325 
Mauchly test of sphericity, P> 0.05, the spherical assumption is not rejected, without correction with 
correction factor ε freedom. 
* Compared with the pre-transplant, P <0.05; Δ compared with 3 months after transplant, P <0.05 
Table 1. Alternation of immune function in patients with SLE before and after AHSCT 
4. Discussion 
Systemic lupus erythematosus is an autoimmune disease, without clear cause and difficult 
to cure. In recent years, with the increasing levels of health care, new drugs and treatments 
are emerging for treatment. Particularly glucocorticoids and cytotoxic drugs for SLE, the 
survival rate has improved significantly. To the 1990s, 5,10,20-year survival rate has reached 
93%, 1 92%, 68%,respectively [5,6]. 
Though corticosteroid treatment with cytotoxic drugs is still the preferred solution, 
However, due to the large amount of medication for a long time, prone to side effects and 
complications and make 60% of patients eventually die from side effects o [7]. Therefore, it 
is still medical problem at home and abroad. 
In 1985, Ikehara confirmed Allo-BMT to treat mice autoimmune disease. In 1991 Knaan-
Shanzer confirmed their bone marrow transplant for adjuvant arthritis in rats. At the 
same time,it was discovered that receiving Allo-BMT or autologous bone marrow 
transplantation can achieve remission for autoimmune disease such as the blood system 
or other malignancies [12]. Karussis et al [13] firstly used cyclophosphamide and 
granulocyte colony-stimulating factor to stimulate the bone marrow to release 
hematopoietic stem cells into the blood, and isolated, purified and separate mouse 
hematopoietic stem cells in vitro. After sorting the total number of CD34+ cells greater 
than 2.0 × 106/kg, use large doses of immunosuppressive agents in the second step for 
abnormal immune cells elimination, then reinfuse the CD34+ cells into mice. After the 
reconstruction of immune system, and long term follow up, it was found that it has 
achieved remarkable results in animal models. 
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In recent years, it is effective that autologous peripheral blood stem cell transplantation for 
autoimmune diseases and becoming a hot topic in international research. Firstly, we use 
doses of immunosuppressive agents or radiation in patients to finish a strong immune 
suppression, and then rebuild the patient's immune system by autologous hematopoietic 
stem cell transplantation. The use of peripheral blood transplantation, hematopoietic stem 
cells has no anesthesia, trauma and has an earlier immune reconstitution compared to bone 
marrow transplantation. The patient's immune regulation in the reconstruction process can 
reach a new equilibrium and (or) immune tolerance, may complete remission or even 
completely cured[7 ~ 11]. 
Hematopoietic stem cell transplantation (HSCT) for the treatment of SLE has opened up a 
new way, however, there is a certain risk, which confined its use. Combined with existing 
research and the experience, the performance of at least one of the following may be 
considered for HCST treatment;  epileptic seizures or psychiatric symptoms;  lung 
involvement at one of the following: pulmonary hemorrhage, infiltration and no infection is 
present, within the last 6 months is greater than 15% lower forced vital capacity, pulmonary 
hypertension;  refractory hemolytic anemia, reticulocyte count is greater than 3%, 
hemoglobin less than 100g / L; or the decreaseing of other fatal blood cells;  SLE disease 
activity index greater than 16 points;  serious anti-cardiolipin antibody syndrome. 
Nephritis and has one of the following persons: proteinuria greater than 1g / d and albumin 
less than 30 g / L, serum creatinine greater than 15mg / L, and hematuria, cellular casts, 
renal biopsy with acute proliferative damage. Patients also need the following therapy: oral 
prednisone 0.5mg/kg at least 2 months, last 6 months or intravenous methyl poured nylon 
1g, 3 times; application CTX 500 mg/m2, 3 times/month [3,7]. 
Stem cells can self-renew,replicate to mature blood cells, has CD34 antigen expressed, 
including hematopoietic progenitor / unique cell populations. The cceptable number of 
CD34+ cell transplantation cellsis in the range (2 ~ 5) × 106/kg, but the number of peripheral 
blood stem cells often less than 0.1%. Therefore, we need a way to increase the concentration 
of peripheral blood stem cells, which is called stem cell mobilization. The key method is 
chemotherapy + granulocyte colony-stimulating factor or single granulocyte colony-
stimulating factor. The former may alleviate the disease, while the later may deteriorate it. 
Joint mobilization is better than single granulocyte-colony stimulating factor, 
cyclophosphamide 4g/m2 than 2g/m2 [3,14,15]. The group of 16 patients were treated  with 
cyclophosphamide 4g/m2 combined granulocyte colony-stimulating factor 5ug/kg to make 
a success rate of 100%. But in the process of collecting peripheral blood stem cells, there are 
two important problems to be solved, that is, when to start and when to end. We need to 
keep abreast of peripheral blood mononuclear cells and stem cells numbers timely for 
clinical decisions.CD34+ cell count is the most widely used in the determination of graft 
stem / progenitor cells of the indicators. The absolute count of which is closely related to 
content, to predict the effect of acquisition. The peripheral blood WBC, MNC count and the 
number of harvested CD34+ cells were not significantly correlated, indicating which does 
not accurately reflect the level of peripheral blood stem cells, so it became the key that the 
absolute count of CD34+ collection . In general, the best collection time should be when the 
peripheral blood CD34+ cells is from 20 to 85 / uL, according to its cell surface antigen and 
labeled antibody to the tiny beads binded specifically. Some scholars [16] reported that 
CD34+ cell graft up to a median of 49% by positive selection, compared with pre-separation 
concentration as 33 times. The main purpose is to remove the graft in the immune cells to 
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reduce the chance of a relapse transplant. We used the German company Miltenyi Biotec 
MACS immunomagnetic system in CD34+ sorting [17]. 
Mobilization of patients with SLE-related complications included fever, hypotension, 
abdominal pain, joint pain, seizures, myocardial infarction, pulmonary edema [17]. The total 
of 16 patients mobilized had both leukopenia and gastrointestinal adverse reactions, with 
varying degrees of fever, while blood cultures negative, after CD34+ cells collected the 
temperature returned to normal but its mechanism remains unclear, needing further study. 
Pretreatment is one of the important part of autologous hematopoietic stem cell 
transplantation. Its main purpose is to destroy the abnormal cells in vivo in patients, 
minimize recurrence, and provided the necessary space to implant. Regimen should also 
have the function to suppress hematopoietic and immune, which often require multiple 
medications and / or radiotherapy combined. 
Currently, there are no uniform for conditioning regimen for SLE. In general, the efficacy of 
pre-clinical and pre-treatment intensity have some relevance, for example, by 
cyclophosphamide / busulfan, cyclophosphamide or other drugs combined with systemic 
lymph node irradiation, the disease recurrence rate is low, but transplant-related mortality 
also increased. Because of the transplanted organ damage associated with SLE patients, 
most scholars do not advocate the use of intense myeloablative program, but the lymphatic 
clearance program. The current use of cyclophosphamide (200mg/kg) + anti-thymocyte 
globulin (ATG, 90mg/kg) is more common, while some individual case reports 
cyclophosphamide (120 ~ 150mg/kg) + systemic lymph node irradiation (400 ~ 600cGy, 
lung shielding to 400cGy) or cyclophosphamide (120mg/kg) + busulfan (16 mg / kg) and 
the BEAM program (BCNU 300mg / m2, VP16 400 ~ 800mg / m2, cytarabine 800 ~ 1600mg 
/ m2, melphalan 140mg / m2) [10,15,18]. The whole body and lymph node irradiation can 
induce more tumor-related complications, should be taken seriously enough [15]. 
Conditioning regimen containing cyclophosphamide, 5% patients emerged life-threatening 
cardiac toxicity and severe cardiac toxicity, mainly showing low-voltage ECG, progressive 
heart failure or pericarditis with the drug doses. One case in our group occurred serious 
heart failure in use of drugs to support and pericardiocentesis when necessary. 
Over 90% patients had the incidence of oral mucositis after hematopoietic stem cell 
transplantation, approximately the date of reinfusion, continuing until blood implanted. 
Some patients have severe pain and require total parenteral parenteral nutrition support 
and make fungal, bacterial, viral and other infections common. 
Almost all patients have varying degrees of gastrointestinal reactions, mainly nausea, 
vomiting, or diarrhea. We can use 5 - hydroxy tryptophan-blockers to control 
gastrointestinal adverse reactions before chemotherapy. 
Renal dysfunction is a common complication with amounts of pathogenic factors, such as 
direct drug toxicity, hypovolemia and use of nephrotoxic drugs. By disabling nephrotoxic 
drugs, paying attention to water and electrolyte balance, most patients can return to 
normal. 
Another prominent side effect caused by cyclophosphamide is hemorrhagic cystitis, 
mainly due to as cyclophosphamide metabolites acrolein from urine, causing extensive 
mucosal ulceration, necrosis and bleeding. The effective prevention measures include 
alkaline urine and application Gomez sodium, which can be combined with acrolein to 
reduce the cell toxicity in a total dose of 1.6 times of that of cyclophosphamide  and 
divided in 4 times. 
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Animal experiments confirmed that the graft of T lymphocytes related to disease recurrence 
after transplantation [3,7,11]. At present, most foreign scholars are using cell sorting system 
to remove T-cell line in vitro, only can remove about 3 logarithmic T cells, which can be re-
entered to arouse the body's own response to the disease clone. ATG is a kind of polyclonal 
immunoglobulin antibodies using the human thymus cells immunized animals to collect the 
serum extract, selective against human T lymphocytes. Anti-thymocyte globulin in the body 
can bind to T cells, swallowed by circulating monocytes, and fixed macrophages 
components, through the activation of complement to remove T cells [19]. We applied 
plenty of ATG in vivo to remove the residual T lymphocytes and memory cells to enhance 
the success rate and reduce the relapse rate. 
The exact mechanism of autologous peripheral blood stem cell transplantation for 
autoimmune diseases is not fully clear, what can be certain is that the original autoimmune 
cell clones were completely destroyed while re-established a normal immune system [7-10]. 
By high dose systemic immunosuppressants or radiation, we eliminate its own mature 
immune cells, while stem cells, due to a large quantity of aldehyde dehydrogenase, can 
resist to cyclophosphamide. Pretreatment process can avoid the impact of memory T cell so 
that the new stem cells can develop into non-anti-self lymphocytes, inducing tolerance to 
the autoantigen. In addition, the mobilization and pre-processing stage eliminate 
autoimmune lymphocytes, reduce antibodies and immune complexes to allow healing of 
damaged tissue and normal immune. 
Autoimmunity and self-tolerance is a dynamic equilibrium between the process. By using 
immunosuppressive agents and hematopoietic stem cell transplantation can eventually 
balance the body's immune system back to normal [11]. Theoretically, it is possible to cure 
autoimmune disease.  
Since 1997, Marmont using autologous bone marrow stem cell transplantation for treatment 
of SLE has been successful, there have been a lot of research on bone marrow and peripheral 
blood stem cell transplantation for treatment of SLE at home and abroad, and have achieved 
encouraging clinical results. In 2003, ASH meeting reported the U.S. total number of cases is 
681, of which 127 cases were systemic lupus erythematosus, mainly in remission. Van lear 
have found that 45 SLE patients undergoing transplantation, 27 of which have significantly 
improved, 14 recurred after the initial alleviation, 7 deaths, for 5 have relation with the 
transplantation and the overall transplant-related mortality rate  is 11% [20]. Traynor et al 
from North America [10] found 15 patients with SLE completing the study of autologous 
transplantation were alive, but 2 died after mobilization. In more than 1 year’s follow-up, 12 
patients, 8 cases completely withdrawaled, 2 have small doses of hormones to maintain, 2 
had disease activity requiring the addition of immunosuppressive agents. Our studies show 
that it has an ideal short-term effect about autologous peripheral blood purified CD34 + cell 
transplantation for SLE, for all patients had hematopoietic reconstitution well, most of the 
clinical manifestations and related immunological parameters disappeared and were 
markedly improved in survival quality. But there are still many issues worth further 
reflection and research [3], such as: SLE multiple genetic abnormalities exist in the stem cell 
gene level, the transplanted stem cells will differentiate into the same self-reactive immune 
cells; whether disease recurrence are related to stem cells derived from the input; if the new 
input stem cells in the relatively normal environment can develop into self-tolerance T, B 
lymphocytes, and so on. 
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methods with stem cells is explored. Clearly, the continued use of biomedical engineering will depend heavily
on stem cells, and this book is well positioned to provide comprehensive coverage of these developments.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ledong Sun and Bing Wang (2012). Autologous Peripheral Blood Purified Stem Cells Transplantation for
Treatment of Systemic Lupus Erythematosus, New Advances in Stem Cell Transplantation, Prof. Taner
Demirer (Ed.), ISBN: 978-953-51-0013-3, InTech, Available from: http://www.intechopen.com/books/new-
advances-in-stem-cell-transplantation/autologous-peripheral-blood-purified-stem-cells-transplantation-for-
treatment-of-systemic-lupus-eryt
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
